2505 Meridian Parkway
310 articles about Chimerix, Inc.
Chimerix Appoints Pratik S. Multani, M.D., to Board of Directors
Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced the appointment of Pratik S. Multani, M.D., to its Board of Directors, effective immediately.
Chimerix to Report Fourth Quarter and Year End 2019 Financial Results and Provide an Operational Update on February 25, 2020
Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Tuesday, February 25, 2020 at 8:30 a.m. ET to report financial results for the fourth quarter and full-year ended December 31, 2019
Chimerix Presents Data Supporting Brincidofovir as a Potential Treatment for Smallpox at 2020 American Society for Microbiology Biothreats Meeting
Brincidofovir demonstrated a statistically significant survival advantage in two well-characterized animal models of lethal orthopoxvirus infection
Chimerix Presents Updated Results from Phase 2 Clinical Trial of DSTAT in Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia at American Society of Hematology Annual Meeting
Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that data relating to its dociparstat sodium (DSTAT) program, formerly known as CX-01, were presented at the 61st American Society of Hematology Annual Meeting, in Orlando, FL.
Chimerix Announces Third Quarter 2019 Financial Results and Provides Operational Update
Final Data from Phase 2 Randomized Trial of DSTAT in First-line AML Support Enhanced Durability of Response, Event-free Survival and Overall Survival Benefit
Chimerix to Present at Upcoming Investor Conferences in November 2019
Chimerix, Inc., a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced that management will present at two upcoming investor conferences in November.
Chimerix to Announce Third Quarter 2019 Financial Results and Provide an Operational Update on November 5, 2019
Chimerix, Inc. announced that it will host a live conference call and audio webcast on Tuesday, November 5, 2019 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2019, and to provide an operational update..
Today has been marked by a wide range of life science and biopharma stories. Here’s a broader look at some of the top stories.
Chimerix Presents Results from Multiple Ascending Dose Study of IV Brincidofovir at IDWeek
Chimerix today announced data from the company’s Phase 1 study evaluating the safety and pharmacokinetics (PK) of multiple ascending doses (MAD) of intravenous (IV) brincidofovir (BCV) in healthy subjects. These data will be presented at IDWeek™ 2018, held October 3-7 in San Francisco, CA.
Landmark AdVance Study Shows Adenovirus Burden Correlates with Mortality in Pediatric Allogeneic Hematopoietic Cell Transplant Recipients
Chimerix today announced the full analysis of adenovirus (AdV) viral load dynamics and all-cause mortality in pediatric patients.
Analyst price targets for these two biotechs suggest they could double your money. Here's what you need to know.
Chimerix Initiates AdAPT Study for Oral Brincidofovir and Advances IV Brincidofovir to Patient Studies
The Company reports the initiation of the AdAPT Study (Adenovirus after Allogeneic Pediatric Transplantation).
Chimerix Announces Third Quarter 2017 Financial Results
Chimerix reported a net loss of $17.3 million, or $0.37 per basic and diluted share, for the third quarter of 2017.
Chimerix to Announce Third Quarter 2017 Financial Results on November 8, 2017
An archived webcast will be available on the Chimerix website approximately two hours after the event.
Chimerix Appoints Heather Knight-Trent, PharmD, As Vice President Of Regulatory Affairs
Chimerix Announces Second Quarter 2017 Financial Results
Chimerix To Announce Second Quarter 2017 Financial Results On August 7, 2017
Chimerix Announces First Quarter 2017 Financial Results
Chimerix To Announce First Quarter 2017 Financial Results On May 9, 2017
Chimerix To Host Annual Investor Update On April 27, 2017